Effects of carteolol and timolol on plasma lipid profiles in older women with ocular hypertension or primary open-angle glaucoma

American Journal of Ophthalmology

Volumn 127, Issue 2, 1999, Pages 142-147

  Stewart, William C ^a,b   Dubiner, Harvey B ^c   Mundorf, Thomas K ^d   Laibovitz, Robert A ^e   Sall, Kenneth N ^f   Katz, L J ^g   Singh, Kuldev ^h   Shulman, David G ^e   Siegel, Les I ⁱ   Hudgins, Alison C ^a   Nussbaum, Lawrence ^j   Apostolaros, Maria ^j  

^a University of South Carolina   (United States)

^b MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^c Clayton Eye Center   (United States)

^d Clayton Eye Center   (United States)

^e Clayton Eye Center   (United States)

^f Clayton Eye Center   (United States)

^g Clayton Eye Center   (United States)

^h Clayton Eye Center   (United States)

ⁱ Glaucoma Center of Michigan   (United States)

^j OTSUKA PHARMACEUTICAL DEVELOPMENT AND COMMERCIALIZATION INC   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CARTEOLOL; CHOLESTEROL; HIGH DENSITY LIPOPROTEIN; LIPID; LOW DENSITY LIPOPROTEIN; TIMOLOL; TRIACYLGLYCEROL;

ADULT; AGED; ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; FEMALE; HUMAN; INTRAOCULAR HYPERTENSION; LIPID BLOOD LEVEL; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MULTICENTER STUDY; OPEN ANGLE GLAUCOMA; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; TOPICAL DRUG ADMINISTRATION; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 0032996585     PISSN: 00029394     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9394(98)00328-6     Document Type: Article

References (25)

1. Stewart WC, Osterman J. Serum lipid physiology and the influence of medication classes used to treat chronic open-angle glaucoma. Surv Ophthalmol. Forthcoming.
2. Leren P. Effect of alpha- and beta-blocker therapy on blood lipids European experience . Am J Med. 75:1984;67-71.
3. National Cholesterol Education Program. Second report of the expert panel on detection, evaluation, and treatment of high blood cholesterol in adults. Adult Treatment Panel II, 1983.
4. Cruickshank J.M. The case for beta-blockers as first-line antihypertensive therapy. J Hypertens. 10:(suppl 3):1992;S21-S27.
5. Burris J.F. β-blockers, dyslipidemia, and coronary artery disease a reassessment . Arch Intern Med. 153:1993;2085-2092.
6. van Brummelen P. The relevance of intrinsic sympathomimetic activity for β-blocker-induced changes in plasma lipids. J Cardiovasc Pharmacol. 5:(suppl):1983;S51-S55.
7. Coleman A.L., Diehl D.L.C., Jampel H.D., et al. Topical timolol decreases plasma high-density lipoprotein cholesterol level. Arch Ophthalmol. 108:1990;1260-1263.
8. Freedman S.F., Freedman N.J., Shields M.B., et al. Effects of ocular carteolol and timolol on plasma high-density lipoprotein cholesterol level. Am J Ophthalmol. 116:1993;600-611.
9. Neter J, Wasserman W, Kutner MH. Analysis of covariance. Applied Linear Statistical Models. Springfield, Illinois: Richard D. Irwin, 1985:884-873.
10. Book SA. Essentials of Statistics. New York: McGraw Hill, 1978:117-122, 205-215.
11. Wilson P.W.F., Castelli W.O., Kannel W.B. Coronary risk prediction in adults (the Framingham Heart Study). Am J Cardiol. 59:(suppl):1987;91G-94G.
12. Castelli W.P., Garrison R.J., Wilson P.W.F., et al. Incidence of coronary heart disease and lipoprotein cholesterol levels the Framingham Study . JAMA. 256:1986;2835-2838.
13. Rosner B. Fundamentals of biostatistics. 1982;301-304 Duxbury Press, Boston.
14. West J., Longstaff S. Topical timolol and serum lipoproteins. Br J Ophthalmol. 74:1990;663-664.
15. Yamamoto T., Kitazawa Y., Noma A., et al. The effects of the β-adrenergic-blocking agents, timolol and carteolol, on plasma lipids and lipoproteins in Japanese glaucoma patients. J Glaucoma. 5:1996;252-257.
16. Sekimoto H., Goto Y., Goto Y., et al. Changes of serum total cholesterol and triglyceride levels in normal subjects in Japan in the past twenty years. Research committee on familial hyperlipidemia in Japan. Jpn Circ J. 47:1983;1351-1358.
17. Simons L.A., Simons J., McCallum J., Friedlander Y. Dubbo study of the elderly hypertension and lipid levels . Atherosclerosis. 92:1992;59-65.
18. Beevers D.G., Johnston J., Devine B.L., et al. Relation between prognosis and the blood pressure before and during treatment of hypertensive patients. Clin Sci Mol Med. 4:(suppl):1978;S333-S336.
19. Sleight P. Beta-adrenergic blockade after myocardial infarction. N Engl J Med. 304:1981;837-838.
20. Johnson B.F. The emerging problem of plasma lipid changes during antihypertensive therapy. J Cardiovasc Pharmacol. 4:(suppl 2):1982;S213-S221.
21. Superko H.R., Haskell W.L., Krauss R.M. Association of lipoprotein subclass distribution with use of selective and non-selective beta-blocker medications in patients with coronary heart disease. Atherosclerosis. 101:1993;1-8.
22. Grimm R.H., Black H. Workshop II. Hypertension trials and meta-analyses is there any value for further studies? Am J Med. 90:(suppl 2A):1991;S24-S25.
23. Toth P.J., Horwitz R.I. Conflicting clinical trials and the uncertainty of treating mild hypertension. Am J Med. 75:1983;482-488.
24. MRC trial of treatment of mild hypertension principal results . Br Med J. 291:1985;97-104.
25. Loaldi A., Montorsi P., Fabbiocchi F., et al. Angiographic evolution of coronary atherosclerosis in patients receiving propranolol. Chest. 99:1991;1238-1242.